Detection of analytes using reorganization energy

• US 6,248,229 B1
• Filed: 10/13/1999
• Issued: 06/19/2001
• Est. Priority Date: 06/12/1997
• Status: Expired due to Term

• Current Assignee: Osmetech Technology Inc. (Roche Holding AG)
• Original Assignee: Clinical Micro Sensors Inc. (Roche Holding AG)
• Inventors: Meade, Thomas J.
• Primary Examiner(s): Prouty, Rebecca E.
• Assistant Examiner(s): MONSHIPOURI, MARYAM
• Application Number:
  US09/417,988
• Time in Patent Office: 615 Days
• Field of Search: 435/4, 435/5, 435/6, 435/7.1, 435/7.2, 435/7.3, 435/7--, 435/7-1-, 435/7--, 205/77.5, 205/777.5, 205/778, 205/779, 205/793.5, 422/68.1, 422/82.01, 422/82.02
• US Class Current: 205/777.5
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: G01N 33/5438 Electrodes

Abstract

The invention relates to novel methods and compositions for the detection of analytes using the nuclear reorganization energy, λ, of an electron transfer process.

Claims

1. A composition for use in a competition assay comprising an electrode comprising:

a) a covalently attached binding ligand, wherein said binding ligand is selected from the group consisting of a target analyte and a target analyte analog; and

b) a covalently attached solvent accessible transition metal complex comprising a metal selected from the group consisting of manganese, technetium, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, palladium, platinum, copper, silver and gold;

such that upon binding of a binding partner of said target analyte or said analog, a solvent inhibited transition metal complex is formed.

2. A composition according to claim 1 wherein said binding partner is an antibody.

3. A composition according to claim 1 wherein said target analyte is a therapeutic drug.

4. A composition according to claim 1 wherein said target analyte is a protein.

5. A composition according to claim 1 wherein said solvent accessible transition metal complex has at least two coordination sites occupied by polar coordination groups.

6. A composition according to claim 1 wherein said solvent accessible transition metal complex has at least one coordination site occupied by a water molecule.

7. A composition according to claim 1 wherein said electrode further comprises a self-assembled monolayer.

8. A composition according to claim 1 wherein said solvent accessible transition metal complex is covalently attached to said electrode via a conductive oligomer.

9. A composition according to claim 1 wherein said binding ligand is covalently attached to said electrode via a conductive oligomer.

10. A composition according to claim 1 wherein said binding ligand is covalently attached to said electrode via a spacer.

11. An apparatus for use in a competition assay for the detection of target analytes comprising:

a) a test chamber comprising a first measuring electrode and at least a second electrode, wherein said first measuring electrode comprises;

i) a covalently attached binding ligand, wherein said binding ligand is selected from the group consisting of a target analyte and a target analyte analog;

ii) a covalently attached solvent accessible transition metal complex comprising a metal selected from the group consisting of manganese, technetium, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, palladium, platinum, copper, silver and gold;

such that upon binding of a binding partner of said target analyte or said analog, a solvent inhibited transition metal complex is formed; and

b) an AC/DC voltage source electrically connected to said test chamber.

12. An apparatus according to claim 11 further comprising a processor.

13. An apparatus according to claim 11 wherein said binding partner is an antibody.

14. An apparatus according to claim 11 wherein said target analyte is a therapeutic drug.

15. An apparatus according to claim 11 wherein said target analyte is a protein.

16. An apparatus according to claim 11 wherein said solvent accessible transition metal complex has at least two coordination sites occupied by polar coordination groups.

17. An apparatus according to claim 11 wherein said solvent accessible transition metal complex has at least one coordination site occupied by a water molecule.

18. An apparatus according to claim 11 wherein said first electrode further comprises a self-assembled monolayer.

19. An apparatus according to claim 11 wherein said solvent accessible transition metal complex is covalently attached to said first electrode via a conductive oligomer.

20. An apparatus according to claim 11 wherein said binding ligand is covalently attached to said electrode via a conductive oligomer.

21. An apparatus according to claim 11 wherein said binding ligand is covalently attached to said electrode via a spacer.